In another prospective pilot study, Grkovski et al. included six oligometastatic (max 3 lesions) BCR PCa after primary therapy, who underwent 2 cycles of [177Lu]Lu-PSMA-617 (7.5 GBq each) and stereotactic body RT (SBRT) after 6 weeks (27 Gy in 3 fractions). Here, FOLH1 is linked to posterior cortical atrophy.